Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Relationship of UV exposure to prevalence of multiple sclerosis in England

(2011) S. V. Ramagopalan et al.   NEUROLOGY

Sun exposure and vitamin D are independent risk factors for CNS demyelination

(2011) R. M. Lucas et al.   NEUROLOGY

Evidence for Polygenic Susceptibility to Multiple Sclerosis—The Shape of Things to Come

(2010)   AMERICAN JOURNAL OF HUMAN GENETICS

Reply

(2010) Florian Doepp et al.   ANNALS OF NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

(2010) Andrew D. Goodman et al.   ANNALS OF NEUROLOGY

Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis

(2010) Dimitrios Karussis et al.   ARCHIVES OF NEUROLOGY

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

(2010) Raju Kapoor et al.   LANCET NEUROLOGY

Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis

(2010) Sergio E. Baranzini et al.   NATURE

T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

(2010) Robert C Axtell et al.   NATURE MEDICINE

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

(2010) J. M. Burton et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Major Histocompatibility Class I Locus Contributes to Multiple Sclerosis Susceptibility Independently from HLA-DRB1*15:01

(2010) Bruce A. C. Cree et al.   PLoS One

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β

(2009) Luca Durelli et al.   ANNALS OF NEUROLOGY

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

(2009) Volker Brinkmann   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: Results from two Phase 1 clinical studies

(2009) Gudarz Davar et al.   CYTOKINE

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

(2009) L. Prosperini et al.   EUROPEAN JOURNAL OF NEUROLOGY

Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

(2009) Jean E. Merrill et al.   JOURNAL OF NEUROLOGY

The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis

(2009) Paolo Zamboni et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency

(2009) Paolo Zamboni et al.   JOURNAL OF VASCULAR SURGERY

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

(2009) Andrew D Goodman et al.   LANCET

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal

Remyelination capacity of the MS brain decreases with disease chronicity

(2009) T. Goldschmidt et al.   NEUROLOGY

Gray matter atrophy in multiple sclerosis: A longitudinal study

(2008) Elizabeth Fisher et al.   ANNALS OF NEUROLOGY

Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

(2008) Bruce D. Trapp et al.   Annual Review of Neuroscience

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE